- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Cannabis and Cannabinoids For the Management of Pain
The International Association for the Study of Pain recently released a statement on the strength of current research on cannabis and cannabinoid use in pain management. What did they find?
Virtually every state that has legalized medical marijuana and other cannabis products has included chronic pain as one of the problems for which these can be prescribed. However, questions remain regarding the strength of the evidence supporting the use of these products for the management of pain.
To determine the extent and quality of such evidence, the International Association for the Study of Pain (IASP)—the leading international pain organization for health care professionals—established a presidential task force to review the evidence and make recommendations on the use of cannabis and cannabinoids for the management of pain. The IASP Presidential Task Force on Cannabis and Cannabinoid Analgesia reviewed existing preclinical and clinical research, and released a position statement on March 16, 2021, in the journal Pain.
In the slides below, find details on what the task force concluded.
